Evoke Pharma Inc. shares plummeted 75.8% in pre-market trade Monday after the company’s diabetic gastroparesis drug for female patients missed its primary endpoint in phase 3 topline results. The company’s president and CEO Dave Gonyer called the results for the drug, EVK-001, “unexpected and an anomaly” and said they continue to believe the drug is a promising treatment option. Evoke shares more than doubled over the last three months, compared with a 3.2% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.